684 related articles for article (PubMed ID: 24022075)
41. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
[TBL] [Abstract][Full Text] [Related]
42. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
43. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
[TBL] [Abstract][Full Text] [Related]
44. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.
Gupta P; Goldenberg DM; Rossi EA; Chang CH
Blood; 2010 Oct; 116(17):3258-67. PubMed ID: 20628151
[TBL] [Abstract][Full Text] [Related]
45. 4. Antibody therapy for malignant lymphoma.
Tobinai K
Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608
[TBL] [Abstract][Full Text] [Related]
46. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
Harjunpää A; Junnikkala S; Meri S
Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
[TBL] [Abstract][Full Text] [Related]
47. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
Gillies SD; Lan Y; Williams S; Carr F; Forman S; Raubitschek A; Lo KM
Blood; 2005 May; 105(10):3972-8. PubMed ID: 15692062
[TBL] [Abstract][Full Text] [Related]
48. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.
Okroj M; Eriksson I; Österborg A; Blom AM
Med Oncol; 2013 Dec; 30(4):759. PubMed ID: 24198205
[TBL] [Abstract][Full Text] [Related]
49. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
50. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
51. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
52. Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
Leonard JP
Clin Adv Hematol Oncol; 2012 Aug; 10(8):540-2. PubMed ID: 23073054
[No Abstract] [Full Text] [Related]
53. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B
Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
[TBL] [Abstract][Full Text] [Related]
54. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
van Meerten T; Rozemuller H; Hol S; Moerer P; Zwart M; Hagenbeek A; Mackus WJ; Parren PW; van de Winkel JG; Ebeling SB; Martens AC
Haematologica; 2010 Dec; 95(12):2063-71. PubMed ID: 20851867
[TBL] [Abstract][Full Text] [Related]
55. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas.
Zhang N; Khawli LA; Hu P; Epstein AL
Clin Cancer Res; 2005 Aug; 11(16):5971-80. PubMed ID: 16115941
[TBL] [Abstract][Full Text] [Related]
56. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
57. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
58. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
Wu L; Wang C; Zhang D; Zhang X; Qian W; Zhao L; Wang H; Li B; Guo Y
Cancer Lett; 2010 Jun; 292(2):208-14. PubMed ID: 20056316
[TBL] [Abstract][Full Text] [Related]
59. Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.
Manzur S; Cohen S; Haimovich J; Hollander N
Clin Exp Immunol; 2012 Dec; 170(3):291-9. PubMed ID: 23121670
[TBL] [Abstract][Full Text] [Related]
60. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
